9,707,257 OCR.pdf (1.17 MB)
Anti-HIV group I introns and uses thereof in treating HIV infections
standard
posted on 2017-08-01, 00:00 authored by Malcolm J. FraserDescribed is a unique class of antiviral molecule that can be applied to control and eliminate HIV infection in patients using myeloablation therapies and replenishment with transformed bone marrow stem cells programmed to express the antiviral molecule. These anti-viral molecules target the HIV genome in a highly conserved domain, and when expressed in cells prior to infection will cause the cell to die upon infection with HIV. Cell death insures no proliferation of new virus. Reconstituting the immune system with cells expressing these antivirals prevents re-establishment of HIV infection from reservoirs in the re-established lymphocyte and macrophage populations. Over time, reservoirs will be depleted entirely, effectively eliminating the virus. In effect, this new type of antiviral can be used to cure HIV infections.
History
Patent Number
US 9707257 B2Other Application
13/096,626Inventor
Malcolm J. FraserInventor from Local Institution
Malcolm J. FraserAssignee
University of Notre Dame du LacDate Modified
2017-08-01Language
- English
Claims
24Prior Publication Number
US 20120276071 A1Publisher
U.S. Patent and Trademark OfficeCooperative Patent Classification Codes
A61K 35/545 (20130101); C12N 15/1132 (20130101); C12N 2310/124 (20130101); C12N 2310/3519 (20130101)Contributor
Malcolm J. FraserInternational Patent Classification Codes
C12N 15/113 (20100101); C12N 15/12 (20060101); C12N 15/11 (20060101); A61K 35/545 (20150101)Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC